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SUMMARY
Introduction Premature ovarian failure (POF) is characterized by amenorrhea, hypergonadotropism 
and hypoestrogenism in women bellow 40 years. Osteoporosis is one of the late complications of POF.
Objective To correlate collagen type I alpha1 (COLIA1) gene polymorphism with bone mineral density 
(BMD) in women with POF.
Methods We determined the COLIA1 genotypes SS, Ss, ss in 66 women with POF. Single nucleotide 
polymorphism (G to T substitution) within the Sp 1-binding site in the first intron of the COLIA1 gene was 
assessed by polymerase chain reaction (PCR) followed by single-stranded conformation polymorphism 
(SSCP) analysis. Bone mineral density (BMD) was measured at the lumbar spine region by dual X-ray 
absorptiometry. Statistics: Kruskal-Wallis ANOVA, Chi-square test, Spearman correlation test.
Results The relative distribution of COLIA1 genotype alleles was SS – 54.4%, Ss – 41.0% and ss – 4.5%. 
No significant differences were found between genotype groups in body mass index, age, duration of 
amenorrhea or BMD. A significant positive correlation was observed between BMI and parity.
Conclusion The COLIA1 gene is just one of many genes influencing bone characteristics. It may act as 
a marker for differences in bone quantity and quality, bone fragility and accelerated bone loss in older 
women. However, in young women with POF, COLIA1 cannot identify those at higher risk for osteoporosis.
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INTRODUCTION
Premature ovarian failure (POF) is character-
ized by the spontaneous cessation of men-
struation in post-pubertal women before the 
age of forty [1]. Women with POF have a 
hypergonadotropic-hypoestrogenic hormone 
profile (follicle stimulating hormone >40 IU/L 
and estradiol <50 pmol/L [2]. Deficiency of 
estrogen, a critical reproductive hormone for 
bone acquisition, is associated with an in-
creased bone turnover and accelerated bone 
loss, leading to the increased susceptibility to 
osteoporosis and bone fractures. Osteoporo-
sis is a common disabling age-related disease 
characterized by reduced bone mineral density 
(BMD), disorganization of skeletal integrity 
and micro-architecture and increased risk of 
fragility fractures [3]. Thus, identification of 
POF subjects with an increased risk for devel-
oping osteoporosis is of primary importance.
The inheritance of bone mass is under poly-
genic control. It accounts for 75-85% of the 
variance in peak bone mass and plays a role 
in regulating bone turnover and rate of bone 
loss [4]. Candidate genes encoding the main 
regulators of bone metabolism are genes for 
calciotrophic hormones, bone matrix proteins, 
steroid hormones and local regulators of bone 
metabolism. The genes regulating local bone 
metabolism are: vitamin D receptor, estrogen 
receptor, androgen receptor, parathyroid hor-
mone, calcitonin receptor, peroxisome prolifer-
ator-activated receptor γ, collagen type I alpha 
1 (COLIA1), α2 HS-glycoprotein, osteocalcin, 
tissue growth factor β-1, interleukin-6 and 1, 
apo E, Ca-sensitizing receptor, colagenase and 
methylenetetrahydrofolate reductase [5].
Grant et al. [6] identified a single nucleotide 
G→T polymorphism affecting the binding site 
for the transcription factor Sp1 in the first in-
tron (+1245 G to T) of the COLIA1 gene lead-
ing to incorrect triple helix organization in a 
region important for the regulation of collagen 
transcription and significantly related to bone 
mass, higher fragility and osteoporosis. This 
raised the possibility that genotyping at this site 
may be of value in identifying women who are 
at risk for osteoporosis [7]. Transcription factor 
Sp1 has higher affinity for the “s” than “S” allele, 
leading to incorrect organization of these chains 
into triple helix and to the higher fragility.
Some studies provided no evidence for the 
link between the polymorphism of the COLIA1 
Sp1 binding site and osteoporosis [8]. The larg-
est multicentric study performed recently in 
Europe by the Genetic Markers for Osteoporo-
sis (GENOMOS) consortium revealed a mod-
est association of COLIA1 polymorphism and 
reduced body mass index [9]. According to the 
available data there are no studies of COLIA1 
genotype and risk for osteoporosis in POF.     
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OBJECTIVE
The aim of this study was to investigate the relationship 
between COLIA1 gene polymorphism and BMD in Ser-
bian women with POF.
METHODS
The study was performed in a group of 66 women with 
POF who were referred for clinical evaluation to the Insti-
tute of Endocrinology, Clinical Center of Serbia, Belgrade, 
Serbia. They were ethnically homogenous and of the same 
socio-economic status and dietary habits. A detailed medi-
cal history was obtained from each woman and her dietary 
calcium intake was assessed using a sequential question-
naire that included food assessment for dietary calcium. 
Exclusion criteria were BMI over 30 kg/m2, bilateral ova-
riectomy, and use of drugs affecting bone metabolism 
(glucocorticoids, thyroxine, bisphosphonates, menopause 
replacement therapy). Women with renal, liver, endocrine 
diseases, rheumatoid arthritis, malignancy, alcoholism, 
and long-term immobilization were also excluded. The 
diagnosis of POF was made according to age (<40 years), 
the length of amenorrhea (>12 months) and two serum 
values of follicle stimulating hormone, FSH >40 IU/L and 
17β estradiol <20 pmol/L. Osteoporosis was diagnosed by 
the T-score that was equal to or greater than -2.5 SD using 
densitometric analysis based on the criteria established by 
the World Health Organization [10].
The Ethics Committee of the Institute of Endocrinol-
ogy, Clinical Center of Serbia, Belgrade, approved the 
study. A written informed consent was obtained from each 
woman who participated in the study.
Each woman was examined clinically and routine bio-
chemical tests were performed to exclude systemic and 
metabolic bone disease. Serum hormone measurements, 
carried out on two consecutive days at 8.00 a.m., follow-
ing an overnight fast, included FSH, luteinizing hormone 
(LH), prolactin, estradiol, progesterone and testosterone. 
Hormone analyses were done by RIA using the standard 
kit (INEP, Zemun, Serbia).
BMD was measured at the lumbar spine (L2-L4) re-
gion by dual energy X ray absorptiometry (DEXA) using 
a Lunar DPX-L densitometer (Lunar Co, Madison, WI). 
The coefficient of variation in vitro CV=1.0% as assessed 
by 300 daily spine phantom measurements. Weight and 
height were measured just prior to the bone mineral 
measurement. BMD was presented in g/cm2. Calculated 
T- score was based on the measurements performed in the 
local population. Z scores were derived from age-matched 
controls.
Genomic DNA analysis was performed in all women. 
Genomic DNA was extracted from peripheral blood 
leukocytes using the standard phenol-chloroform pro-
cedure and analyzed by electrophoresis on 1% agar-
ose gel. A rapid PCR/SSCP-based method was used for 
screening the polymorphism in the promoter of CO-
LIA1. The oligonucleotide primer set was designed to 
yield PCR fragment of 160 bp. The upstream primer was 
5’-GAGTGGCTTGCGTGGTAGAG-3ć, and the down-
stream primer was 5’-ACATTTCAAGTCTTGGGGGG-3’. 
PCR was performed in a final volume of 25 ml containing 
200 ng DNA and 1 U of Stoffel Taq polymerase (Perkin 
Elmer) on a Techne Genius Termocycler system. The PCR 
protocol was 30 cycles of 96°C for 1 minute, and 72°C for 2 
minutes and a final performed at 94°C for 2 minutes. PCR 
products were analyzed by electrophoresis on 2% agarose 
gel, and resolved on 18% polyacrylamide gel with 5% glyc-
erol. Bands on the gel were visualized by silver staining.
Parameters of various genotype groups were compared 
by the Kruskal-Wallis ANOVA test. The Chi-square test 
was used to compare distributions of categorical clini-
cal data. Correlation analyses were performed using the 
Spearman test. Hardy–Weinberg equilibrium was also 
tested by the Tools for population, the Genetic analysis 
program Monte Carlo method with 40,000 random per-
mutations (11). All the calculations were performed with 
the SPSS statistical package (SPSS Inc. Chicago Illinois, 
USA). A p-value <0.05 was considered statistically sig-
nificant.
RESULTS
The subjects were distributed into three subgroups, ac-
cording to the COLIA1 gene polymorphism, namely SS, 
Ss, and ss. Only one woman had the “ss” allele. Baseline 
characteristics of the groups are shown in Table 1. No 
significant difference between groups was found for age, 
age at menarche, duration of amenorrhea, parity, mater-
nal menopausal age, dietary calcium intake (except for a 
woman in the Ss group who had insufficient calcium in-
take), smoking habits (45% were smokers), BMI or waist/
hip ratio. The hormonal parameters were characterized by 
elevated FSH (68.3±8.4 IU/L) and LH (38±5.6 IU/L) and 
low levels of estradiol (38.2±10.7 pmol/L), progesterone 
(2.1±0.9 nM/L) and testosterone (1.2±0.6 nM/L). Prolactin 
was in normal range (310.6±68.2 nmol/L).
No significant difference was found between the groups 
in age, age at menarche, amenorrheic period, delivery, ma-
ternal menopause age, body mass index (BMI), waist and 
hip ratio (W&H) and Z score (Table 1).
The genotype frequencies in women with POF were SS 
– 54.5%, Ss – 41.0%, and ss – 4.5%, whilst allele frequen-
cies in the Hardy–Weinberg equilibrium were SS -68.4%, 
Table 1. The baseline characteristics of the study subjects (mean±SD)
Genotype SS group Ss group
Age (years) 40.8±4.9 41.7±3.5
Age at menarche (years) 14.7±2.1 12.6±1.2
Amenorrheic period (years) 6.7±6.2 6.9±6.6
Delivery (times) 1.0±0.7 1.8±1.6
Maternal menopausal age (years) 48.6±5.9 48.3±5.8
Body Mass Index (kg/m2) 24.4±3.0 26.1±5.4
Waist/hip ratio 0.8±0.1 0.8±0.1
Z score L2-L4 BMD (g/cm2) -0.9±1.5 -0.4±1.6
BMD – bone mineral density  
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Ss - 35.09%; and ss - 4.4% (Graph 1). This indicated some 
non-significant excess heterozygozity in POF women. In 
120 Serbian women of normal menopausal age, genotype 
frequencies were SS - 66.6 % homozygotes and Ss - 24.1% 
heterozygotes [12].
No difference was seen between the groups with respect 
to lumbar spine BMD (Graph 2). The Ss group had 47% 
higher Z score than the SS group (-0.44 vs. -0.93). Whilst 
the SS group showed a negative correlation between BMI 
and Z score (R=-0.16), in the Ss group a positive correla-
tion was present (R=0.06), but both were non-significant. 
Obese women (BMI>25.0 kg/m2) showed a positive cor-
relation between BMI and Z score (R=0.25). A signifi-
cant positive correlation was found for BMI and parity 
(R=0.61, p<0.05) indicating that women with more than 
two children were more obese. A non-significant negative 
correlation was found for the duration of amenorrhea in 
years and Z score (<5 amenorrheic years, R=-0.4, >5 years, 
R=-0.34) (Graphs 3 and 4). Also, a non-significant nega-
tive correlation was found for age and Z score (R=-0.17) 
and age at menarche and Z score (R=-0.37).
DISCUSSION
The essential task of BMD measurements is to identify 
women with POF at increased risk for osteoporosis, thereby 
enabling appropriate treatment. This is the first study to in-
vestigate COLIA1 gene polymorphism in women with POF.
Type I collagen, a major protein of bone, is a heterodimer 
with two collagen chains encoded by the genes COLIA1 and 
2 [13]. A single nucleotide G→T polymorphism is associ-
ated with increased binding affinity for the Sp1 protein in 
the COLIA1 gene, increased allele specific transcription of 
COLIA1, increased production of collagen protein and dif-
ference in bone strength [5]. Ss heterozygotes seem to have 
lower BMD and higher risk for osteoporosis and fractures.
A meta analysis of data from sixteen published stud-
ies including a total 4965 individuals showed a significant 
association between carriage of the COLIA1 "s" allele and 
low BMD [14, 15]. Bone tissue cores obtained from Ss 
genotype women had reduced inorganic content and in-
creased organic content, when compared with cores ob-
tained from SS genotype women, possibly reflecting ab-
normalities in mineralization in Ss genotypes. Individuals 
with the "ss" genotype had an altered ratio between the 
amounts of COLIA1 and 2 which could lead to reduced 
peak bone mass or a higher risk of trabecular perforation 
during age or menopause-related high bone turnover. It 
seems that the major defect in osteoporosis is not in the 
"osteoblast" per se, but in the mechanism for ensuring that 
a significant number of osteoblasts are assembled in the 
right place at the right time.
Women with POF have a insignificantly higher hetero-
zygosity compared with allele frequencies in the Serbian 
women with normal menopause and Hardy–Weinberg 
equilibrium. We have not found published data of allele 
frequencies in women with POF in other countries.
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Graph 1. Prevalence of genotype subgroups
POF – premature ovarian failure; SERBIA – normal postmenopausal women in 
Serbia; HARDY – Hardy–Weinberg equilibrium
Graph 2. Z score in genotype subgroups
Graph 3. Correlation of BMD-Z score and amenorrheic period (in 
years) in SS group
Graph 4. Correlation of BMD-Z score and amenorrheic period (in 
years) in Ss group
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Our findings are in agreement with Liden et al. [16] 
who found no significant differences between genotype 
groups with regard to lumbar spine BMD, although this 
probably reflects the small number of subjects with the "ss" 
homozygous genotype. This is not surprising, considering 
that the estimated incidence of POF is only 0.9-3% of the 
population [17].
The correlation between the age and BMD is one of 
the most important in most studies of osteoporosis. BMD 
declines with age and genetic effects on bone density could 
be mediated by differences in the age-related rate of bone 
loss as well as by differences in peak bone density. Bone 
mass at any time point after 35 years of age is a function 
of the peak bone mass attained at a younger age and of the 
annual rate of bone loss. Women with POF are younger 
than women participating in most postmenopausal stud-
ies, thus their age-related bone loss rate is unknown. 
When the subjects in the study of Uitterlinden et al. [15] 
were divided into five-year categories, the differences in 
BMD between genotype groups were smaller in younger 
menopausal women (55-65 years), but became higher 
with increasing age. They concluded that the genetic ef-
fect on BMD associated with the COLIA1 locus is stronger 
in postmenopausal than in premenopausal women. In a 
group of postmenopausal women, Langdahl et al. [7] also 
found that individuals with the ss genotype had signifi-
cantly lower BMD, but they were older than Ss group. 
Most studies have found a marked decrease of bone mass 
between age 40 and 60 years. Thus, our finding of COLIA1 
gene polymorphism not being associated with reduced 
bone density in a heterozygote group of young women 
with POF is not unexpected. We did not find significant 
correlation between BMD and aging, which probably re-
flected both a small number of subjects studied and their 
relatively narrow age span. It would be very interesting to 
follow BMD changes in our patients over the next 10-20 
years, as this would reflect the effect of aging on bones.
As BMI is an important factor for BMD, the differences 
in BMD have been accompanied by the differences in body 
weight. Obesity, as reflected by BMI >25 kg/m2, appear to 
influence BMD positively. Whilst Hadjidakis et al. [18] 
observed a significant positive correlation between ver-
tebral mineral density and BMI in the immediate period 
following the last menstruation and in all age segments 
in POF, in our study there was a positive correlation only 
in the Ss group (R=0.06). This could be explained as the 
influence of endocrine activity of adipose tissue on bone 
metabolism. We found a statistically significant correlation 
between BMI and parity.
Although COLIA1 alleles have been found by some 
workers to predict fractures after correction for BMD, 
other investigators have found no association between the 
COLIA1 genotype and BMD or osteoporotic fractures [16, 
19]. Some other factors contribute to the risk of osteoporot-
ic fractures including advancing age, low BMI, previous 
fractures, muscle weakness and impaired vision. In our 
group only one woman with the Ss genotype had multi-
ple fractures. She is now 44 years old, menarche was at 13 
years, amenorrheic period was 20 years, previously she had 
regular cycles, BMI was 24.2 kg/m2, and waist/hip ratio was 
0.8. However, her calcium intake was insufficient, as she 
disliked dairy products, and she also smoked. Additionally, 
she had rheumatoid arthritis and Sicca syndrome. Thus, 
there were a number of factors other than polymorphism 
which could have been responsible for her osteoporosis.
There are many gene-gene and gene-environment in-
teractions which determine the skeletal phenotype. Bone 
mass is under the control of many genes with relatively 
small effects, rather than few genes with a large effect, as 
Kobayashi et al. [20] have observed. Our results are con-
sistent with previous findings [21] that different genes 
seem to act in various combinations, causing individual 
degrees of susceptibility in given persons.
CONCLUSION
The COLIA1 gene polymorphism may principally act as 
a marker of increased bone fragility and accelerated bone 
loss in older women, rather than a marker of lower peak 
bone mineral density. It may be a marker of differences in 
bone quality (bone structure or matrix composition, as 
well as bone quantity).
Further genetic studies on other candidate genes are 
required, due to the multifactorial nature of the disease. 
The aim of the future studies will be to define genes regu-
lating bone mass and bone turnover, their interactions 
and interactions with environmental factors leading to 
osteoporosis.
The complex biology of the skeleton with so many fac-
tors involved in skeletal growth and development and the 
universal nature of age-related bone loss make it extremely 
unlikely that there is a single gene for osteoporosis. This 
would explain why the genetic markers studied to date ac-
count for only a small part of the variance in bone mineral 
density.
Complex future genetic studies of women with POF 
may answer the question of their premature aging and 
faster “biological clock”. Pharmacogenomics of drug re-
sponsiveness may in future determine the selection of pa-
tients with POF for a given effective therapy.
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КРАТАК САДРЖАЈ
Увод Пре  вре  ме  на ин  су  фи  ци  јен  ци  ја јај  ни  ка (ПИЈ) се од  ли  ку-
је аме  но  ре  јом, хи  пер  го  на  до  тро  пи  змом и хи  по  е  стро  ге  ни  јом 
код же  на мла  ђих од 40 го  ди  на. Осте  о  по  ро  за је ка  сна ком-
пли  ка  ци  ја овог ста  ња.
Ци  ља ра  да Циљ ис  тра  жи  ва  ња је био да се упо  ре  де ген  ски 
по  ли  мор  фи  зам ко  ла  ге  на тип I ал  фа 1 (CO LIA1) са гу  сти  ном 
ко  шта  не ма  се код же  на са ПИЈ.
Ме  то  де ра  да Од  ре  ђи  ван је CO LIA1 ге  но  тип SS, Ss и ss код 66 
же  на са ПИЈ по  мо  ћу есе  ја за ре  ак  ци  ју лан  ча  ног умно  жа  ва  ња 
ДНК (енгл. polyme ra se chain re ac tion – PCR). По  ли  мор  фи  зам 
јед  ног ну  кле  о  ти  да (за  ме  на G у T) у окви  ру Sp1 ве  зу  ју  ћег ме-
ста у пр  вом ин  тро  ну ге  на CO LIA1 од  ре  ђи  ван је при  ме  ном 
PCR, на  кон че  га се при  сту  пи  ло ана  ли  зи кон  фор  ма  ци  о  ног по-
ли  мор  фи  зма. Гу  сти  на ко  шта  не ма  се је ме  ре  на на ни  воу лум-
бал  ног де  ла кич  ме по  мо  ћу ап  сорп  ци  о  ме  три  је. Хор  мон  ске 
ана  ли  зе за фо  ли  ку  ло  сти  му  ли  шу  ћи хор  мон, лу  те  и  ни  зира  ју  ћи 
хор  мон, естра  ди  ол, про  лак  тин, про  ге  сте  рон и те  сто  сте  рон 
ура  ђе  не су при  ме  ном ме  то  да RIA. При ста  ти  стич  кој об  ра  ди 
по  да  та  ка ко  ри  шће  ни су: Кра  скал–Во  ли  сов (Kru skal–Wal lis) 
ANO VA тест, χ2-тест и Спир  ма  нов (Spe ar man) тест ко  ре  ла  ци  је.
Ре  зул  та  ти Ре  ла  тив  на ди  стри  бу  ци  ја але  ла CO LIA1 ге  но  ти  па 
би  ла је: SS 54,4%, Ss 41,0% и ss 4,5%. Ни  је утвр  ђе  на зна  чај  на 
раз  ли  ка из  ме  ђу гру  па пре  ма ге  но  ти  пу за гу  сти  ну ко  шта  не 
ма  се, ста  рост ис  пи  та  ни  ца, пе  ри  од аме  но  ре  је или ин  декс те-
ле  сне ма  се же  на. Зна  чај  на по  зи  тив  на ко  ре  ла  ци  ја је уоче  на 
за ин  декс те  ле  сне ма  се и па  ри  тет.
За  кљу  чак CO LIA1 је са  мо је  дан од мно  гих ге  на ко  ји ути  чу на 
ка  рак  те  ри  сти  ке ко  сти. Код же  на ста  ри  је жи  вот  не до  би он   
мо  же би  ти мар  кер ква  ли  те  та, кван  ти  те  та и осе  тљи  во  сти ко-
сти. Код мла  дих же  на са ПИЈ CO LIA1 не мо  же да ука  же на оне 
же  не код ко  јих по  сто  ји ве  ћи ри  зик за на  ста  нак осте  о  по  ро  зе.
Кључ  не ре  чи: CO LIA1; ген  ски по  ли  мор  фи  зам; пре  вре  ме  на 
ин  су  фи  ци  јен  ци  ја јај  ни  ка; осте  о  по  ро  за
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